RxDoctor Payments Data

Xiao Chun Yang, MD

Geriatric Medicine · Silver Spring, MDNPI 1932162278

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Gilead accounts for 66.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $489 and has fallen 75.1% since, to $122 in 2024.

$1,587in general payments, 2019–2025

Across 55 payments — averaging $28.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • GSK$171
  • AstraZeneca$158
  • Amgen$90
  • Pfizer$54
  • Merck$18
  • plus $38 from 3 others

What the payments were for

  • Food & beverage$1,587100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead35$1,059
GSK9$171
AstraZeneca3$158
Amgen1$90
Pfizer3$54
Merck1$18
Boehringer Ingelheim1$14
AbbVie1$12
Dentsply Sirona Inc1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,587 in reported general payments places this provider in the 80th percentile of 112 geriatric medicine providers in Maryland.

See all geriatric medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$76,584
Medicare patients
115
Services billed
1,516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin24$24,373
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,823
FarxigaDapagliflozin Propanediol11$13,236
Metoprolol Succinate69$1,258
Rosuvastatin Calcium88$1,247
Allopurinol17$1,224
Atorvastatin Calcium90$934
Tamsulosin Hcl67$700
Telmisartan14$635
Montelukast Sodium54$603
Azelastine Hcl22$598
Amlodipine Besylate80$596
Pravastatin Sodium44$557
Losartan Potassium81$539
Famotidine13$406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$14$24,37324 claims
GSKTrelegy Ellipta$171$14,82316 claims
AstraZenecaFarxiga$158$13,23611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 112 geriatric medicine providers in Maryland.

Other geriatric medicine in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →